What the platform can already answer

Cell therapies have huge potential, but cost, complexity, and centralised manufacturing have kept many of them confined to last-line use. In this episode, Dr Andree Bates speaks with Armon Sharei, Founder and CEO of Portal Biotechnologies, about what happens when AI meets cell engineering, and why point-of-care delivery could make personalised cell programming more practical, scalable, and safer.

Armon explains Portal’s core idea: cells are programmable machines. If you can reliably deliver multiple cargoes into cells, you can instruct new behaviours. Portal’s method briefly “squishes” cells through precision pores to disrupt the membrane so external material can enter, opening the door to complex cell engineering without permanent genome edits.

They explore where AI fits in: modelling cell behaviour. By combining perturbation experiments, rich readouts, and phenotypic screening, AI can help generate “virtual cell models” that suggest which RNA instructions to deliver to drive specific outcomes. The bottleneck is data at the right complexity, because many effects only appear when multiple pathways are changed at once.

A key takeaway is the safety and flexibility of transient RNA reprogramming. Unlike irreversible genetic modification, RNA fades within days, reducing long-term risk and making earlier-line use more realistic. Armon also discusses how point-of-care workflows may be regulated differently, with the machine treated as a device and the cargo as the drug.

Looking ahead, he paints a vision of infusion-centre cell programming: a compact system that takes blood, delivers tailored RNA instructions to immune cells, and returns them within hours, potentially bringing costs closer to mainstream biologics and expanding access.

Topics Covered

• Why delivery is the unlock for programmable cell therapies
• How Portal’s “cell squishing” delivery works
• Using AI to model cells and generate functional programmes
• The data bottleneck and why multi-perturbation datasets matter
• Phenotypic screening and lab-to-clinic feedback loops
• Transient RNA reprogramming vs permanent genetic modification
• Regulatory implications of point-of-care engineering
• Economics and scalability of point-of-care approaches
• Near-term opportunities in oncology and autoimmunity
• The future vision for infusion-centre personalised therapies

Eularis helps pharma and biotech leaders turn AI activity into board-defensible strategy and measurable commercial outcomes.

If your organisation has plenty of AI in motion but very little that moves the commercial needle in a way the board can see, start with our 10-Day AI Diagnostic Sprint. It’s a focused diagnostic that surfaces what’s actually broken and what’s blocking results, before you invest in a larger strategy effort.

The Sprint diagnoses the problem. The AI Strategic Blueprint that follows is where we build the board-defensible strategy and plan.Details at eularis.com.

About the Podcast

AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.

AI platforms and tools solve specific problems. Strategy makes sure you’re solving the right ones, in the right order. If you want help mapping priorities as you evaluate what to roll out next, send me a LinkedIn DM starting with ‘PRIORITIES’ and two lines: what’s already in flight, and the decision you’re trying to make next.

Dr. Andree Bates LinkedIn | Facebook | X